# SLC6A15

## Overview
SLC6A15 is a gene that encodes the protein solute carrier family 6 member 15, also known as B0AT2, which is a sodium-dependent neutral amino acid transporter. This protein is a member of the solute carrier family 6 and is characterized by its 12 transmembrane domains, which facilitate the transport of essential amino acids such as leucine, valine, isoleucine, methionine, and proline across cell membranes (Pramod2013SLC6; Schraut2020Loss). B0AT2 is predominantly expressed in neurons and astrocytes, particularly in brain regions like the hypothalamus, where it plays a significant role in amino acid metabolism, neurotransmitter synthesis, and the regulation of food intake and energy homeostasis (Hägglund2013B0AT2). The gene has been implicated in various psychiatric disorders, including major depressive disorder, due to its influence on neurotransmitter pathways and stress response mechanisms (Quast2013Functional; Schraut2020Loss). Additionally, SLC6A15 has been identified as a potential tumor suppressor in papillary thyroid cancer, highlighting its diverse roles in human health and disease (Chen2021SLC6A15).

## Structure
The SLC6A15 protein is a member of the solute carrier family 6, which functions as a sodium-dependent symporter for neutral amino acids such as proline, leucine, isoleucine, and methionine (Schraut2020Loss). The primary structure of SLC6A15 consists of a sequence of amino acids that form the protein, which is characterized by 12 transmembrane domains typical of SLC6 transporters (Pramod2013SLC6). These transmembrane domains contribute to the secondary structure, which includes alpha helices that span the cell membrane.

The tertiary structure of SLC6A15 involves the 3D folding of these transmembrane domains, forming a structure that facilitates the transport of amino acids across the cell membrane. This structure is similar to the LeuT fold, which is characterized by a 5 + 5 helical architecture, where transmembrane segments form two antiparallel pentahelical bundles (Pramod2013SLC6). The quaternary structure may involve the assembly of multiple subunits, although specific details on this aspect are not provided in the context.

Post-translational modifications such as phosphorylation and glycosylation may affect the function and localization of SLC6A15, although specific modifications are not detailed in the provided context. Splice variants may result in isoforms with different functional properties, but specific isoforms are not mentioned in the context.

## Function
The SLC6A15 gene encodes a protein that functions as a sodium-dependent neutral amino acid transporter, primarily active in neurons. This transporter is involved in the uptake of essential branched-chain amino acids (BCAAs) such as leucine, valine, and isoleucine, as well as methionine and proline, into cells (Hägglund2013B0AT2). In the brain, SLC6A15 plays a crucial role in amino acid metabolism and neurotransmitter synthesis, which are vital for normal neuronal function (Quast2013Functional).

The protein encoded by SLC6A15, known as B0AT2, is expressed in neurons and astrocytes, with significant expression in the hypothalamus and other brain regions involved in food intake regulation and energy homeostasis (Hägglund2013B0AT2). It is involved in leucine homeostasis and mediates the anorexigenic effect of leucine, influencing food intake and neuronal activation in response to amino acids (Hägglund2013B0AT2).

SLC6A15 is also associated with psychiatric disorders, as it is involved in the synthesis of neurotransmitters like glutamate and GABA, which are linked to psychiatric conditions (Quast2013Functional). The gene's expression impacts brain chemistry and behavior, potentially affecting mood and stress resilience (Schraut2020Loss).

## Clinical Significance
The SLC6A15 gene has been implicated in several psychiatric disorders, particularly major depressive disorder (MDD). Variants in this gene, such as the single nucleotide polymorphism (SNP) rs1545843, have been associated with increased risk of depression. Carriers of the AA genotype of this SNP exhibit higher adrenocorticotropic hormone (ACTH) and cortisol responses, worse cognitive performance, and reduced hippocampal volumes compared to carriers of at least one G allele. This risk allele is linked to down-regulation of SLC6A15 expression in the hippocampus, potentially contributing to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and cognitive impairments observed in MDD (Quast2013Functional; Schuhmacher2013A).

The SLC6A15 gene is also involved in the regulation of glutamate transmission, which is crucial for brain function and stress response. Alterations in SLC6A15 expression can affect glutamate levels, hippocampal volume, and neuronal integrity, influencing emotional behavior and stress susceptibility (Ayka2020The; Wang2017A). Animal studies have shown that SLC6A15-knockout mice exhibit anxiety and depressive-like behaviors under chronic social stress, further supporting its role in stress-related psychiatric disorders (Choi2016Effects).

In addition to its role in psychiatric conditions, SLC6A15 has been identified as a tumor suppressor in papillary thyroid cancer (PTC). Downregulation of SLC6A15 in PTC correlates with increased tumor invasiveness, suggesting its potential as a therapeutic target (Chen2021SLC6A15).

## Interactions
SLC6A15, a member of the solute carrier family, is involved in several protein interactions that influence its function and stability. One significant interaction is with KLHL36, a potential cullin-based E3 ligase adaptor. This interaction is crucial for the regulation of SLC6A15 protein stability, as overexpression of KLHL36 leads to a decrease in SLC6A15 stability, suggesting that it is targeted for degradation by a KLHL36-associated cullin-based RING E3 ligase (Frommelt2024The). 

SLC6A15 is also stabilized by inhibitors of the autophagy-lysosomal pathway, such as Bafilomycin A1, indicating that this pathway plays a role in its degradation (Frommelt2024The). The interaction between SLC6A15 and KLHL36 has been confirmed at physiological expression levels, highlighting its potential impact on disease susceptibility, including depression (Frommelt2024The).

In the context of papillary thyroid cancer, SLC6A15 interacts with ICAM1, a protein known to promote cancer progression. Overexpression of SLC6A15 leads to the downregulation of ICAM1, suggesting an inhibitory interaction that may contribute to its tumor-suppressive effects (Chen2021SLC6A15). These interactions underscore the multifaceted role of SLC6A15 in cellular processes and disease mechanisms.


## References


[1. (Choi2016Effects) Sunyoung Choi, Kyu-Man Han, June Kang, Eunsoo Won, Hun Soo Chang, Woo Suk Tae, Kyu Ri Son, Su-Jin Kim, Min-Soo Lee, and Byung-Joo Ham. Effects of a polymorphism of the neuronal amino acid transporter slc6a15 gene on structural integrity of white matter tracts in major depressive disorder. PLOS ONE, 11(10):e0164301, October 2016. URL: http://dx.doi.org/10.1371/journal.pone.0164301, doi:10.1371/journal.pone.0164301. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0164301)

[2. (Chen2021SLC6A15) Yuxin Chen, Hai Li, Weiwei Liang, Yan Guo, Miaoguan Peng, Wen Ke, Haipeng Xiao, Hongyu Guan, and Yanbing Li. Slc6a15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer. Journal of Cellular Biochemistry, 122(8):814–826, March 2021. URL: http://dx.doi.org/10.1002/jcb.29914, doi:10.1002/jcb.29914. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.29914)

[3. (Schuhmacher2013A) Anna Schuhmacher, Leonhard Lennertz, Michael Wagner, Susanne Höfels, Ute Pfeiffer, Vera Guttenthaler, Wolfgang Maier, Astrid Zobel, and Rainald Mössner. A variant of the neuronal amino acid transporter slc6a15 is associated with acth and cortisol responses and cognitive performance in unipolar depression. International Journal of Neuropsychopharmacology, 16(1):83–90, February 2013. URL: http://dx.doi.org/10.1017/s1461145712000223, doi:10.1017/s1461145712000223. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.1017/s1461145712000223)

[4. (Hägglund2013B0AT2) Maria G. A. Hägglund, Sahar Roshanbin, Erik Löfqvist, Sofie V. Hellsten, Victor C. O. Nilsson, Aniruddha Todkar, Yinan Zhu, Olga Stephansson, Jana Drgonova, George R. Uhl, Helgi B. Schiöth, and Robert Fredriksson. B0at2 (slc6a15) is localized to neurons and astrocytes, and is involved in mediating the effect of leucine in the brain. PLoS ONE, 8(3):e58651, March 2013. URL: http://dx.doi.org/10.1371/journal.pone.0058651, doi:10.1371/journal.pone.0058651. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0058651)

[5. (Schraut2020Loss) Karla‐Gerlinde Schraut, Oleksandra Kalnytska, Daniel Lamp, Martin Jastroch, Matthias Eder, Felix Hausch, Nils C. Gassen, Sarah Moore, Nagarjuna Nagaraj, Juan P. Lopez, Alon Chen, and Mathias V. Schmidt. Loss of the psychiatric risk factor slc6a15 is associated with increased metabolic functions in primary hippocampal neurons. European Journal of Neuroscience, 53(2):390–401, October 2020. URL: http://dx.doi.org/10.1111/ejn.14990, doi:10.1111/ejn.14990. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/ejn.14990)

[6. (Wang2017A) Lijuan Wang, Zhifen Liu, Xiaohua Cao, Jianying Li, Aixia Zhang, Ning Sun, Chunxia Yang, and Kerang Zhang. A combined study of slc6a15 gene polymorphism and the resting-state functional magnetic resonance imaging in first-episode drug-naive major depressive disorder. Genetic Testing and Molecular Biomarkers, 21(9):523–530, September 2017. URL: http://dx.doi.org/10.1089/gtmb.2016.0426, doi:10.1089/gtmb.2016.0426. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/gtmb.2016.0426)

[7. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[8. (Ayka2020The) Asli Ayka and Ahmet Özer Şehirli. The role of the slc transporters protein in the neurodegenerative disorders. Clinical Psychopharmacology and Neuroscience, 18(2):174–187, May 2020. URL: http://dx.doi.org/10.9758/cpn.2020.18.2.174, doi:10.9758/cpn.2020.18.2.174. This article has 83 citations.](https://doi.org/10.9758/cpn.2020.18.2.174)

9. (Frommelt2024The) The solute carrier superfamily interactome. This article has 0 citations.

[10. (Quast2013Functional) Carina Quast, Serena Cuboni, Daniel Bader, André Altmann, Peter Weber, Janine Arloth, Simone Röh, Tanja Brückl, Marcus Ising, Anna Kopczak, Angelika Erhardt, Felix Hausch, Susanne Lucae, and Elisabeth B. Binder. Functional coding variants in slc6a15, a possible risk gene for major depression. PLoS ONE, 8(7):e68645, July 2013. URL: http://dx.doi.org/10.1371/journal.pone.0068645, doi:10.1371/journal.pone.0068645. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0068645)